The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index; 31 of the 57 sources its claims cite were checked for support.
Adherence to treatment with artemether–lumefantrine or amodiaquine–artesunate for uncomplicated malaria in children in Sierra Leone: a randomized trial
Open accessAbstract
BACKGROUND: Prompt, effective treatment of confirmed malaria cases with artemisinin-based combination therapy (ACT) is a cornerstone of malaria control. Maximizing adherence to ACT medicines is key to ensuring treatment effectiveness. METHODS: This open-label, randomized trial evaluated caregiver adherence to co-formulated artemether-lumefantrine (AL) and fixed-dose amodiaquine-artesunate (AQAS) in Sierra Leone. Children aged 6-59 months diagnosed with malaria were recruited from two public clinics, randomized to receive AL or AQAS, and visited at home the day after completing treatment. Analyses were stratified by site, due to differences in participant characteristics and outcomes. RESULTS: Of the 784 randomized children, 680 (85.6%) were included in the final per-protocol analysis (340 AL, 340 AQAS). Definite adherence (self-reported adherence plus empty package) was higher for AL than AQAS at both sites (Site 1: 79.4% AL vs 63.4% AQAS, odds ratio [OR] 2.16, compared to probable adherence plus probable or definite non-adherence, 95% confidence interval [CI] 1.34-3.49; p = 0.001; Site 2: 52.1% AL vs 37.5% AQAS, OR 1.53, 95% CI 1.00-2.33, p = 0.049). However, self-reported adherence (ignoring drug package inspection) was higher for both regimens at both sites and there was no strong evidence of variation by treatment (Site 1: 96.6% AL vs 95.9% AQAS, OR 1.19, 95% CI 0.39-3.63, p = 0.753; Site 2: 91.5% AL vs 96.4% AQAS, OR 0.40, 95% CI 0.15-1.07, p = 0.067). In Site 2, correct treatment (correct dose + timing + duration) was lower for AL than AQAS (75.8% vs 88.1%, OR 0.42, 95% CI 0.23-0.76, p = 0.004). In both sites, more caregivers in the AQAS arm reported adverse events (Site 1: 3.4% AL vs 15.7% AQAS, p < 0.001; Site 2: 15.2% AL vs 24.4% AQAS, p = 0.039). CONCLUSIONS: Self-reported adherence was high for both AL and AQAS, but varied by site. These results suggest that each regimen has potential disadvantages that might affect adherence; AL was less likely to be taken correctly at one site, but was better tolerated than AQAS at both sites. Measuring adherence to anti-malarials remains challenging, but important. Future research should focus on comparative studies of new drug regimens, and improving the methodology of measuring adherence. TRIAL REGISTRATION: Clinicaltrials.gov, NCT01967472. Retrospectively registered 18 October 2013, https://clinicaltrials.gov/ct2/show/NCT01967472.
Overview
CoChat Summary
## TL;DR
This open-label randomized trial in Sierra Leone compared caregiver adherence to co-formulated artemether–lumefantrine (AL) versus fixed-dose amodiaquine–artesunate (AQAS) in children aged 6–59 months. Self-reported adherence was high for both regimens, but package-based adherence and correct treatment varied by site, with AL better on definite adherence and AQAS better on correct treatment at one site.
## Key findings
- Of 784 randomized children, 680 (85.6%) were included in the final per-protocol analysis: 340 in the AL group and 340 in the AQAS group.
- Definite adherence was higher for AL than AQAS at both sites:
- Site 1: 79.4% AL vs 63.4% AQAS, OR 2.16, 95% CI 1.34–3.49, p = 0.001
- Site 2: 52.1% AL vs 37.5% AQAS, OR 1.53, 95% CI 1.00–2.33, p = 0.049
- Self-reported adherence was >90% for both regimens and showed no strong evidence of treatment differences:
- Site 1: 96.6% AL vs 95.9% AQAS, p = 0.753
- Site 2: 91.5% AL vs 96.4% AQAS, p = 0.067
- In Site 2, correct treatment was lower for AL than AQAS: 75.8% vs 88.1%, OR 0.42, 95% CI 0.23–0.76, p = 0.004. More caregivers in the AQAS arm reported adverse events at both sites (Site 1: 3.4% vs 15.7%; Site 2: 15.2% vs 24.4%).
## Methods
- Open-label, randomized trial conducted at two government-run outpatient facilities in Freetown, Sierra Leone, among children aged 6–59 months with positive malaria RDTs.
- Children were randomized to AL or AQAS and visited at home the day after treatment completion; 784 were randomized, and analyses were stratified by site.
- Primary adherence outcomes were based on self-report plus package inspection, recoded into self-reported adherence and package-based adherence; analyses used per-protocol as the main approach and compared results with intention-to-treat.
## Limitations
- The paper states that adherence measures were limited by bias: self-report is subject to social desirability bias, and package inspection depends on whether packaging is retained.
- The authors state that participant, caregiver, and household characteristics differed substantially between the two sites, so results were stratified by site; they note this variability may influence adherence.
- The paper states that exclusions after randomization and incorrect treatment allocation were unexpectedly frequent, especially at Site 2, though sensitivity analyses found ITT and per-protocol results were almost identical.
- Evident from the text: the study was open-label and participants/providers were not blinded, and home visits could have altered behavior, both of which may have inflated adherence estimates.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
12 Valid · 1 Not valid · 9 Not checked · 62 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Furthermore, evidence of the impact of co-formulation on adherence to ACT remains limited [3].”
§ Adherence to treatment with artemether–lumefantrine or amodiaquine–artesunate for uncomplicated malaria in children in Sierra Leone: a randomized trial > Background
What the sources say
- Supportedcites [3] Banek K, Lalani M, Staedke SG, Chandramohan D. Adherence to artemisinin-based combination therapy for the treatment of malaria: a systematic review of the evidence. Malar J. 2014;13:7. source
The Discussion’s limitations section says only seven studies compared adherence between ACT formulations, leaving critical information lacking. The Results also report no adherence data for the co-formulated versions of ASMQ or DHA-PQ. These passages support the claim that evidence about co-formulation’s impact on adherence remains limited. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Moreover, although this study did occur under ‘normal conditions’, the fact that providers and caregivers were observed, may have altered their behaviour as a result of participating in the study (participation bias), and influenced adherence outcomes [29, 69].”
§ Adherence to treatment with artemether–lumefantrine or amodiaquine–artesunate for uncomplicated malaria in children in Sierra Leone: a randomized trial > Discussion
What the sources say
- Supportedcites [29] Bruxvoort K, Goodman C, Kachur SP, Schellenberg D. How patients take malaria treatment: a systematic review of the literature on adherence to antimalarial drugs. PLoS ONE. 2014;9:e84555. source
The Discussion (page unavailable) says that patients’ awareness of being studied may change medication-taking behaviour and that observing consultations may change dispensers’ advice and patients’ attentiveness and adherence. The Results (Adherence results; page unavailable) likewise indicate that observed consultations may be associated with higher adherence. The paper discusses patients rather than caregivers specifically, but supports the participation-bias mechanism cited here. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [69] Leonard K, Masatu MC. Outpatient process quality evaluation and the Hawthorne effect. Soc Sci Med. 2006;63:2330–40. source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Effectiveness trials and cross-sectional studies have been shown to report higher adherence levels than prospective observational studies; however, even results from such studies vary [3, 30].”
§ Adherence to treatment with artemether–lumefantrine or amodiaquine–artesunate for uncomplicated malaria in children in Sierra Leone: a randomized trial > Discussion
What the sources say
- Supportedcites [3] Banek K, Lalani M, Staedke SG, Chandramohan D. Adherence to artemisinin-based combination therapy for the treatment of malaria: a systematic review of the evidence. Malar J. 2014;13:7. source
The Discussion’s “Study designs” section says cross-sectional surveys and effectiveness studies reported higher adherence levels in its comparison of study designs, while noting that study design may account for the difference. The Results’ “Adherence to ACT” section also documents variation in reported adherence rates. Page numbers are not provided in our copy. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [30] Yeung S, White NJ. How do patients use antimalarial drugs? A review of the evidence. Trop Med Int Health. 2005;10:121–38. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The complexity of the AL dosing regimen, including the number of tablets, twice daily dosing, the requirement to give the second dose 8 h after the first, and to administer with fatty food [43], has been shown to negatively impact treatment adherence [44, 45].”
§ Adherence to treatment with artemether–lumefantrine or amodiaquine–artesunate for uncomplicated malaria in children in Sierra Leone: a randomized trial > Discussion
What the sources say
- Not checked yetcites [43] Novartis. Coartem monograph. vol. 4th ed. Basel: Novartis Pharma AG; 2005.
- Partly supportedcites [44] Gore-Langton GR, Alenwi N, Mungai J, Erupe NI, Eves K, Kimwana FN, et al. Patient adherence to prescribed artemisinin-based combination therapy in Garissa County, Kenya, after three years of health care in a conflict setting. Malar J. 2015;14:125. sourceExperimental — accuracy not yet measured
The Background describes AL’s comparatively complicated dosing regimen and lists treatment-schedule complexity among factors affecting adherence, but does not establish that complexity reduces adherence. In Results > Patient adherence, the only significant predictor in the multivariate model was patients’ recall of correct dosing instructions, not regimen complexity. The copy provides no page numbers for these passages. (LLM, conf=0.85)
- Partly supportedcites [45] Lin JT, Juliano JJ, Wongsrichanalai C. Drug-resistant malaria: the era of ACT. Curr Infect Dis Rep. 2010;12:165–73. sourceExperimental — accuracy not yet measured
The Artemether-Lumefantrine section (page not provided) identifies twice-daily dosing and the need for a fat-containing meal as obstacles to optimal outcomes. It does not say that AL’s dosing complexity has been shown to reduce treatment adherence; it also reports high cure rates with unsupervised dosing. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This variability in findings reflects differences in the retention of the drug package by caregivers, which was significantly higher at Site 1 than at Site 2 (263 [75.8%] vs 185 [52.6%], respectively, p < 0.001; Additional file 1).”
§ Adherence to treatment with artemether–lumefantrine or amodiaquine–artesunate for uncomplicated malaria in children in Sierra Leone: a randomized trial > Results > Adherence
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 84 claims and to verify the 4 references still open.
- It may state two separate claims as one. 31
- Probably not a substantial claim. 29
Citations
Cites
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974 · cited 1×
“Although package inspections and pill counts serve as a gold standard for measuring adherence to treatment of other diseases [54, 65] the heterogeneity of this outcome measure in malaria studies limits comparison of adherence to regimens across studies.”
BackgroundKirk, J., MacDonald, A., Lavender, P., Dean, J., & Rubin, G. (2017) · Biomedicine Hub · doi:10.1159/000480347 · Cited by 3,887
Constructing socio-economic status indices: how to use principal components analysis
Vyas, S., & Kumaranayake, L. (2006) · Health Policy and Planning · doi:10.1093/heapol/czl029 · Cited by 3,280 · cited 1×
“The wealth index was created using principle component analysis (PCA) [31].”
MethodFarmer, K. C. (1999) · Clinical Therapeutics · doi:10.1016/s0149-2918(99)80026-5 · Cited by 889 · cited 2×
“Although package inspections and pill counts serve as a gold standard for measuring adherence to treatment of other diseases [54, 65] the heterogeneity of this outcome measure in malaria studies limits comparison of adherence to regimens across studies.”
BackgroundOutpatient process quality evaluation and the Hawthorne Effect
Leonard, K., & Masatu, M. C. (2006) · Social Science & Medicine · doi:10.1016/j.socscimed.2006.06.003 · Cited by 278 · cited 1×
“Moreover, although this study did occur under ‘normal conditions’, the fact that providers and caregivers were observed, may have altered their behaviour as a result of participating in the study (participation bias), and influenced adherence outcomes [29, 69].”
ResultEffects of the West Africa Ebola Virus Disease on Health-Care Utilization – A Systematic Review
Brolin Ribacke, K. J., Saulnier, D. D., Eriksson, A., & von Schreeb, J. (2016) · Frontiers in Public Health · doi:10.3389/fpubh.2016.00222 · Cited by 257
Do fixed-dose combination pills or unit-of-use packaging improve adherence? A systematic review.
CONNOR, J. L., Rafter, N., & Rodgers, A. (2004) · Europe PMC (PubMed Central) · Cited by 194
Walker, P. G. T., White, M. T., Griffin, J. T., Reynolds, A., Ferguson, N. M., & Ghani, A. C. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)70124-6 · Cited by 167
Mubi, M., Janson, A., Warsame, M., Mårtensson, A., Källander, K., Petzold, M. G., Ngasala, B., Maganga, G., Gustafsson, L. L., Massele, A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019753 · Cited by 155
Fogg, C., Bajunirwe, F., Piola, P., Biraro, S., Checchi, F., Kiguli, J. M., Namiiro, P., MUSABE, J., KYOMUGISHA, A., & Guthmann, J. (2004) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2004.71.525 · Cited by 138 · cited 1×
“A variety of approaches have been used to incorporate package inspection in the classification of adherence outcome [36, 59, 60].”
Method
Research works printed but not linked: 8
- WHO. T3: test, treat, track initiative. Geneva: World Health Organization; 2012.
- WHO. Guidelines for the treatment of malaria. 3rd ed. Geneva: World Health Organization; 2015.
- National Malaria Control Programme (NMCP). Guidelines for case management of malaria. Freetown: Government of Sierra Leone Ministry of Health and Sanitation; 2015.
- WHO. Guidelines for the treatment of malaria. 2nd ed. Geneva: World Health Organization; 2010.
- Sierra Leone Ministry of Health and Sanitation. Guidelines for case management of malaria in Sierra Leone. 3rd ed. Freetown: Sierra Leone Ministry of Health and Sanitation; 2010.
- WHO. World Malaria Report 2016. Geneva: World Health Organization; 2017.
- Novartis. Coartem monograph. vol. 4th ed. Basel: Novartis Pharma AG; 2005.
- Drugs for Neglected Diseases Initiative (DNDi). Press Pack for ASAQ. 2007.
Cited by
Strategies to Improve Antimicrobial Utilization with a Special Focus on Developing Countries
Godman, B., Egwuenu, A., Haque, M., Malande, O. O., Schellack, N., Kumar, S., Saleem, Z., Sneddon, J., Hoxha, I., Islam, S., et al. (2021) · Life · doi:10.3390/life11060528 · Cited by 237
Godman, B., McCabe, H., Leong, T. D. D., Mueller, D., Martin, A. P., Hoxha, I., Mwita, J. C., Rwegerera, G. M., Massele, A. Y., Costa, J. D. O., et al. (2020) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2020.1734456 · Cited by 110
“may enhance its overall utility in routine clinical care [272].”
BackgroundInfluentialYeka, A., Manego, R. Z., Ouoba, S., Tiono, A. B., Kaguthi, G., Bonzela, J., Duong, T. T., Nahum, A., Bouyou-Akotet, M. K., Ogutu, B. R., et al. (2021) · Malaria Journal · doi:10.1186/s12936-021-03749-4 · Cited by 61
Zupko, R., Nguyen, T. D., Ngabonziza, J. C. S., Kabera, M., Li, H., Tran, T. N.-A., Tran, K. T., Uwimana, A., & Boni, M. F. (2023) · Nature Medicine · doi:10.1038/s41591-023-02551-w · Cited by 41
“…in practice, 100% compliance is unlikely and adherence rates may be complicated by under-dosing, over-dosing and formulation design (that is, fixed-dose combination versus copackaged blister packs), resulting in real-world compliance rates between 65% and 90% for a 3-d course of treatment 33,34 .”
BackgroundGarg, S., Gurung, P., Dewangan, M., & Nanda, P. (2020) · Malaria Journal · doi:10.1186/s12936-020-03285-7 · Cited by 21
Metadata
- Authors
- Banek, K., Webb, E. L., Smith, S. J., Chandramohan, D., & Staedke, S. G.
- Affiliations
- London School of Hygiene & Tropical Medicine (GB)
- Ministry of Health and Sanitation (SL)
- Corresponding author
- Banek, Kristin
- Venue
- Malaria Journal
- Published
- 2018-06-04
- Volume
- 17
- Issue
- 1
- Pages
- 222-222
- ISSN
- 1475-2875 (ISSN-L)
- PMC
- PMC5987409
- OpenAlex
- W2806362238
- Semantic Scholar
- bb2e84a607aaff4560e4818525dae2a865974964
- Cited by
- 25
- References
- 62
- Citations by year
- 2026: 2 · 2023: 3 · 2022: 3 · 2021: 12 · 2020: 3 · 2019: 2
- FWCI
- 3.97
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Malaria Journal (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- American Association of University Women
- Medical Research Council (MR/K012126/1)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
- Keywords
- medication adherence, artemether-lumefantrine, uncomplicated malaria, pediatric malaria, artemisinin-based combination therapy, fixed-dose combination, self-reported adherence, caregiver adherence, Sierra Leone
- MeSH terms
- Artemether, Lumefantrine Drug Combination, Amodiaquine, Antimalarials, Child, Child, Preschool, Drug Combinations, Female, Humans, Infant, Malaria, Male, Patient Compliance, Retrospective Studies, Sierra Leone, Artemisinins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adherence to treatment with artemether–lumefantrine or amodiaquine–artesunate for uncomplicated malaria in children in Sierra Leone: a randomized trial. https://app.cochat.ai/papers/10.1186/s12936-018-2370-x
- The paper
- Banek, K., Webb, E. L., Smith, S. J., Chandramohan, D., & Staedke, S. G. (2018). Adherence to treatment with artemether–lumefantrine or amodiaquine–artesunate for uncomplicated malaria in children in Sierra Leone: a randomized trial. Malaria Journal. https://doi.org/10.1186/s12936-018-2370-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

